Clinical Use of Ultrasensitive Cardiac Troponin I Assay in Intermediate- and High-Risk Surgery Patients
Table 1
Baseline characteristics of all patients, stratified by the occurrence of 30-day cardiovascular events.
All patients (142)
Cardiovascular events
Yes ()
No ()
Men
69 (48.6)
7 (43.8)
62 (49.2)
0.79
Age, years
0.80
ASA scoring system
0.47
Class II
52 (36.6)
4 (25)
48 (38.1)
Class III
85 (59.9)
12 (75)
73 (57.9)
Class IV
5 (3.5)
0
5 (4)
Specific Activity Scale*
0.002
Class I
48 (33.8)
4 (25)
44 (34.9)
Class II
40 (28.2)
2 (12.5)
38 (30.2)
Class III
32 (22.5)
2 (12.5)
30 (23.8)
Class IV
13 (9.2)
6 (37.5)
7 (5.5)
Revised Cardiac Risk Index
0.29
Class II
13 (9.2)
1 (6.3)
12 (9.5)
Class III
84 (59.2)
8 (50)
76 (60.3)
Class IV
45 (31.7)
7 (43.8)
38 (30.2)
Smoking
33 (23.2)
4 (25)
29 (23)
0.89
Hypertension
122 (85.9)
14 (87.5)
108 (85.7)
1.00
Diabetes mellitus
58 (40.8)
7 (43.8)
51 (40.5)
0.79
Atrial fibrillation
13 (9.2)
2 (12.5)
11 (8.7)
0.64
History of congestive heart failure
25 (17.6)
5 (31.3)
20 (15.9)
0.16
Left ventricular ejection fraction (%)**
0.20
History of myocardial infarction
48 (33.8)
6 (37.5)
42 (33.3)
0.78
Previous percutaneous coronary intervention
23 (16.2)
6 (37.5)
17 (13.5)
0.025
Previous coronary artery bypass graft
16 (11.3)
3 (18.8)
13 (10.3)
0.39
History of cerebrovascular disease
47 (33.1)
6 (37.5)
41 (32.5)
0.78
Renal impairment***
35 (24.6)
5 (31.3)
30 (23.8)
0.54
Peripheral artery disease
30 (21.1)
9 (56.3)
21 (16.7)
0.001
Preoperative laboratory tests
Hemoglobin, mg/dL
0.43
Serum creatinine, mg/dL
1.12 0.87–1.74
1.48 1.07–2.9
1.09 0.86–1.70
0.23
Creatinine clearance, mL/min
0.53
NT-proBNP, pg/mL
329.3 117.4–1730
1336 181–10175
288 107–1303
0.038
Preoperative medication
Aspirin
65 (45.8)
8 (50)
57 (45.2)
0.79
Clopidogrel
11 (7.7)
1 (6.3)
10 (7.9)
0.39
Insulin
31 (21.8)
6 (37.5)
25 (19.8)
0.12
Statins
75 (52.8)
8 (50)
67 (53.2)
1.00
β-Blockers
72 (50.7)
11 (68.8)
61 (48.4)
0.18
ACE inhibitors
85 (59.9)
10 (62.5)
75 (59.5)
1.00
Data are expressed as number (percentage), mean ± SD, or median interquartile range as appropriate. value indicates differences between patients with and without primary cardiovascular events. ASA: American Society of Anesthesiologists; NT-proBNP: N-terminal pro-B-type natriuretic peptide; ACE: angiotensin-converting enzyme. , ; serum creatinine 2 mg/dL or renal replacement therapy.
